Celltrion’s Humira Biosimilar Receives U.S. FDA Interchangeability Designation for all Its Approved Dosages and Strengths
The U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations.